Overview
INJ and DBR rarely move in perfect sync. Today’s print ($5.13/$1,882.43) and 24h leaders (Injective) help frame which side currently carries relative strength.
Quick winners
Full comparison
| Metric | INJ | DBR |
|---|---|---|
| Price | $5.13 | $1,882.43 |
| Market Cap | $490.41M | $82.13M |
| FDV | — | — |
| Volume 24h | $2.59M | $698,074.00 |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 286.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | DBR |
|---|---|---|
| 1H | — | — |
| 24H | +3.91% | -1.00% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | DBR |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.47 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 59.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Technically, Injective shows RSI 49.29 with trend bias neutral, while DBR sits at RSI 49.02 (bearish). Divergences between momentum and price should be confirmed on higher timeframes.
Fundamentals
| Metric | INJ | DBR |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
DBR
Pros and cons
Pros of Injective
- Injective has an established coin page footprint on PEPS for continuous monitoring.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
Cons of Injective
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
Pros of DBR
- Narrative optionality around DBR can reprice quickly when catalysts appear.
- DBR can offer higher relative beta when market attention rotates toward its niche.
- Diversifying versus Injective with DBR can change portfolio factor exposure.
Cons of DBR
- Weaker market-cap standing may leave DBR more exposed to liquidity droughts.
- Higher volatility on DBR cuts both ways and demands stricter risk limits.
- Smaller book depth versus large caps can increase slippage for DBR.
Which looks stronger right now?
On the latest snapshot, market-cap leadership belongs to Injective, while short-term performance leans toward Injective. That mix suggests relative strength can flip quickly, so size risk accordingly.
AI summary
Comparing INJ and DBR begins with structure: capitalization, volume and rank. Present prints are $5.13 versus $1,882.43. Momentum and trend can disagree with market-cap hierarchy. That is normal in crypto rotations and should be stress-tested against supports and news flow. Canonical URLs prevent duplicate DBR-vs-INJ pages, keeping SEO equity on one comparison. Keep monitoring winners as data updates.
FAQ
Which is better, Injective or DBR?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or DBR?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and DBR.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.